Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anormed has begun enrolling HIV patients into its new clinical trial to evaluate the potential of its CXCR4 entry inhibitor, AMD070.
Subscribe to our email newsletter
In order to enter and infect cells HIV must bind to either the CXCR4 or CCR5 receptor, AMD070 is designed to stop the virus from entering the cells via the CXCR4 receptor.
“AMD070 is the first anti-HIV drug candidate that targets the HIV entry co-receptor CXCR4,” said Dr Stephen Becker, director of clinical Development, Anormed. “The use of CXCR4 by HIV is known to occur in up to 40% of patients, especially those with more advanced disease, and those failing other treatment options.”
The trial is being conducted at two leading HIV research centers, one in the US and one in the UK, and is an open label dose finding study which may include up to 4 study cohorts of 12 patients each.
Patients in the first cohort will receive 200 mg of AMD070, twice daily, for 10 consecutive days. The objective of the study is to determine the safety and antiviral activity of AMD070 in HIV-infected patients who harbor the CXCR4 using virus. Initial data from this study is expected in early 2006.